Idiopathic interstitial pneumonia medical therapy: Difference between revisions
Ahmed Zaghw (talk | contribs) Created page with "__NOTOC__ {{Idiopathic interstitial pneumonia}} {{CMG}}; {{AE}} {{AZ}}; ==Overview== ==Medical Therapy== ==References== {{reflist|2}} {{WH}} {{WS}} Category:Pulmonology..." |
Ahmed Zaghw (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
As IIPs are heterogenous group of unknown interstitial lung disease with different natural history and clinical course, their management should be based on the clinical subtype. Optimal therapy for IPF is controversial as all currently available medications for IPF are severely limited by the lack of clear understanding of the natural history of IPF, the presence of various forms of study designs; heterogeneous patient groups, disputable diagnostic certainty; variable study duration; differences in medication formulation, dosage, route of administration, and duration of treatment; lack of placebo controls; variable intervals between evaluations and differing types of non quantitative assessment criteria. To date, most of treatment strategies have been based on eliminating or suppressing the inflammatory component. As no pharmacological therapy has been proven a clinical efficacy in altering or reversing the inflammatory process of IPF. | |||
==Medical Therapy== | ==Medical Therapy== | ||
==References== | ==References== | ||
Revision as of 19:23, 20 November 2013
|
Idiopathic Interstitial Pneumonia Microchapters |
|
Differentiating Idiopathic interstitial pneumonia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Idiopathic interstitial pneumonia medical therapy On the Web |
|
American Roentgen Ray Society Images of Idiopathic interstitial pneumonia medical therapy |
|
Idiopathic interstitial pneumonia medical therapyin the news |
|
Directions to Hospitals Treating Idiopathic interstitial pneumonia |
|
Risk calculators and risk factors for Idiopathic interstitial pneumonia medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2];
Overview
As IIPs are heterogenous group of unknown interstitial lung disease with different natural history and clinical course, their management should be based on the clinical subtype. Optimal therapy for IPF is controversial as all currently available medications for IPF are severely limited by the lack of clear understanding of the natural history of IPF, the presence of various forms of study designs; heterogeneous patient groups, disputable diagnostic certainty; variable study duration; differences in medication formulation, dosage, route of administration, and duration of treatment; lack of placebo controls; variable intervals between evaluations and differing types of non quantitative assessment criteria. To date, most of treatment strategies have been based on eliminating or suppressing the inflammatory component. As no pharmacological therapy has been proven a clinical efficacy in altering or reversing the inflammatory process of IPF.